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Abstract In non-small cell lung cancer (NSCLC), both USP7
expression and p53 gene status were reported to be an indica-
tor of poor prognosis in adenocarcinoma patients; however, its
roles and mechanisms in lung squamous cell carcinoma and
large cell carcinoma need to be clarified. The USP7 expres-
sion was examined in NSCLC tumors (excluding adenocarci-
noma), their corresponding non-tumorous tissues, and
NSCLC cells. Then, the prognostic role of USP7 was ana-
lyzed in 110 NSCLC samples (excluding the adenocarcino-
ma). Finally, the roles and mechanisms of USP7 in the prolif-
eration, metastasis, and invasion of a NSCLC cell were
assessed using a specific vshRNA. The USP7 expres-
sion was higher in NSCLC tissues compared to non-
tumorous samples, accordingly, the high level of USP7
was detected in NSCLC cell lines compared with HBE
cell. After the USP7 downregulation, the H460 cells
exhibited decreased metastasis/invasion in vitro and
in vivo. The preliminary mechanism study indicated
overexpression of USP7 might regulate the p53-MDM2
pathway by inducing the MDM2 de-ubiquitination and
subsequent stabilization, which resulted in the upregula-
tion of the Bad phosphorylation. Additionally, we also
found that USP7 might induce cell epithelial-
mesenchymal transition to enhance the cell invasive
ability. Clinically, USP7 overexpression significantly
correlated with malignant phenotype. Furthermore, the
5-year overall survival in patients with USP7low was
higher than that of USP7high. Multivariate analysis
showed USP7 overexpression was an independent prog-
nostic marker for these cancers. USP7 overexpression
may regulate the survival and invasive properties of
squamous cell carcinoma and large cell carcinoma cells,
and may serve as a molecular target.
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Lung cancer is a highly aggressive malignancy and the lead-
ing cause of cancer-related mortality worldwide. Non-small
cell lung cancer (NSCLC) accounts for nearly 85 % of lung
cancer cases. Despite great improvements in diagnostic
technology and the introduction of new therapeutic
agents in recent years, the 5-year survival rate of
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NSCLC patients remains dismal due to NSCLC cell
invasion and metastasis prior to treatment [1, 2]. There-
fore, it is essential to identify new sensitive and specific
molecular markers for the early detection and therapeu-
tic targeting of NSCLC.
USP7 (also known as herpesvirus-associated ubiquitin-spe-
cific protease, HAUSP) was originally identified as a
herpesvirus-associated cellular factor and subsequently shown
to deubiquitinate and stabilize p53 [3]. Previous studies
showed that USP7 can target several key regulatory proteins,
including tumor suppressors, DNA repair proteins, immune
responders, viral proteins, epigenetic modulators [4], such as
the herpes simplex virus type 1 (HSV1) Vmw110 interacting
protein, Epstein-Barr nuclear antigen 1 (EBNA1), p53 regu-
lator murine double minute (MDM2), PTEN, INK4a,
TSPYL5, Ataxin-1, and the transcription factors FOXO4,
and REST. USP7 deubiquitinase activity on these substrates
can enhance protein stability and alter the subcellular locali-
zation of targets. Recent studies have shown that the overex-
pression of USP7 in prostate cancer correlates with tumor
aggressiveness and that the inhibition of USP7 can induce
the apoptosis of multiple myeloma (MM) cells resistant to
conventional and bortezomib therapies [5, 6]. Thus, contrary
to initial reports, high levels of USP7 may promote tumor
progression.
USP7 knockout mice die during early embryonic
development compared to wild-type mice, and USP7
knockout embryos show p53 activation and cell growth
arrest [7]. In NSCLC, Masuya et al. reported that USP7
mRNA expression was significantly lower in adenocar-
cinomas than in squamous cell carcinomas, and 45.0 %
patients showed reduced expression of USP7 and the
reduction of USP7 gene expression was reported to play
an important role in adenocarcinomas through p53-
dependent pathways [8], However, the detailed roles of
USP7 in NSCLC should be performed to clarify, for
example, the expression of USP7 in NSCLC compared
with the corresponding non-tumorous tissues and its
roles and mechanisms in lung squamous cell carcinomas
and large cell carcinoma.
Here, we found USP7 expressed high in NSCLC
tissues (excluding the adenocarcinoma tissues) compared
with adjacent non-tumorous tissues. Furthermore, the
increased USP7 expression is positively correlated with
cancer stage, lymph node metastasis, and tumor size.
Importantly, high level of USP7 expression was found
to be associated with the poor outcome of lung cancer
patients (excluding the adenocarcinoma patients). The
knockdown of USP7 in NSCLC cells impaired cell
invasion and motility, and tumor formation, and induced
cell apoptosis. Thus, USP7 might be used as a prog-
nostic factor and therapeutic target in treating lung
squamous cell carcinomas and large cell carcinoma.
Materials and methods
Animals
Male athymic BALB/c nude mice (4 weeks old, Shanghai
Institute of Material Medicine, Chinese Academy of Science)
were raised in specific pathogen-free conditions. All animal
experiments were done in accordance with a protocol ap-
proved by the Shanghai Medical Experimental Animal Care
Commission.
Cell lines and cell transfection
The cell lines A549, H460, H1299, H1355, 95-D, and 95-C
were purchased from the Institute of Biochemistry and Cell
Biology at the Chinese Academy of Science. The cells were
maintained in Dulbecco Modified Eagle medium (DMEM) or
RPMI 1640 supplemented with 10 % fetal bovine serum and
1 % penicillin-streptomycin.
The pGMLV-SC5RNAi lentiviral vectors were pur-
chased from Shanghai Genomeditech Co. Ltd, and the
vshRNA were constructed and synthesized by Shanghai
Genomeditech Co. Ltd. The lentiviral vector was
transfected into cells according to the manufacturer’s
instructions. The sequence strands of vshRNAs are
shown in Supplementary Table 1.
Patients and follow-up
Archival specimens were obtained from 110 patients of lung
cancer (including squamous cell carcinomas and large cell
carcinoma) at Zhongshan Hospital (Shanghai, People’s Re-
public of China) in 2005 with informed consent. All patients
who underwent curative resection for NSCLC were included
in our study. All patients underwent standard lobectomy and
mediastinal lymph node dissection. Paraffin blocks were only
selected if suitable formalin-fixed, paraffin-embedded tissue
and complete clinicopathologic and follow-up data for
the patients were available. Tumor stage was determined
according to the tumor/lymph node/metastasis (TNM)
classification using the seventh edition of the Interna-
tional Union Against Cancer Staging Manual. Patholog-
ic classification was based on World Health Organiza-
tion criteria. Follow-up was completed in July 2010 and
the median follow-up was 43 months (range, 1–
66 months). Overall survival (OS) was defined as the
interval between surgery and death or between surgery
and the last observation for surviving patients. The data
were censored at the last follow-up for living patients.
Ethical approval was obtained from the Zhongshan Hos-
pital Research Ethics Committee.
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Real-time quantitative reverse transcription PCR and Western
blot analysis
Total RNA was extracted using the TRI Reagent (Sigma-
Aldrich, St. Louis,MO, USA) according to the manufacturer’s
protocol. Complementary DNAwas synthesized from 2 μg of
total RNA using random hexamers (Proligo, Boulder, CO)
and SuperScript III Reverse Transcriptase (Invitrogen, Carls-
bad, CA). RT-PCR was carried out on a panel of cell lines and
tumor samples. The real-time quantitative reverse transcrip-
tion PCR (qRT-PCR) conditions were as follows: 1 min at
95 °C, denaturation at 95 °C for 5 s, annealing at 60 °C for
30 s, and extension at 72 °C for 60 s. As follows are the
primers of USP7: 5′-GTTGTTGGAGCGATTACAAGA-3′
and 5′-AAACTGGTCCTCTGCGACTATC-3′; β-actin: 5′-
GGCATCCTGGGCTACACTGA-3′ and 5′-GTGGTCGTTG
AGGGCAATG-3′. Relative expression among samples was
calculated by the comparative CT method. All experiments
were performed in triplicate.
Thirty micrograms of total extract protein was run on SDS-
polyacrylamide gel electrophoresis gels, transferred onto
polyvinylidene difluoride membranes, and incubated with
the corresponding antibodies. The membranes were de-
veloped with the enhanced chemiluminescence method
(Pierce, Rockford, IL, USA). The primary antibodies
used were USP7 (1:1,000, Abcam, UK). β-Actin protein
detection using β-actin antibodies (1:2,000, Beyotime,
China) was used as an internal control. All experiments
were performed in triplicate.
Proliferation assay, monolayer colony formation assay,
and cell apoptosis assay
According to the manufacturer’s instructions, CCK8
(Beyotime, China) was used to measure the proliferation of
H460-vshUSP7, A549-vshUSP7, and control cells. The spe-
cific process was previously described [9].
For the colony formation assay, cells were planted into
three 6-cm cell culture dishes (1,000 cells per dish) and
incubated for 12 days. Plates were washed with PBS then
stained with Giemsa. Colonies with more than 50 cells were
counted.
According to the manufacturer’s instructions, an Annexin
V-PE Apoptosis Detection Kit (KeyGEN Biotech, China) was
used to measure apoptosis in the H460, H460-vshUSP7,
A549, and A549-vshUSP7 cells. First, 2×105 cells were col-
lected and then washed twice with PBS. Cells were then
resuspended in 500 μl binding buffer and transferred to the
EP tube. After adding 1 μl Annexin V-PE and mixing at room
temperature, samples were placed in the dark for 15 min. Cell
apoptosis was then detected by flow cytometry. Experiments
were repeated in triplicate.
Cell invasion assays
Cell invasion assays were performed using 24-well transwell
plates (Corning, NY, USA) precoated with Matrigel (Fal-
con354480; BD Biosciences, Franklin Lakes, NJ, USA).
The lower chambers were filled with growth media and the
upper chambers were filled with media and 1 % FBS. A549
cells were seeded in the upper chamber of inserts at a density
of 1×105 cells per well. After 24 h, the inserts were removed
and washed, the upper Matrigel layer removed, and the mem-
brane and Matrigel were fixed in 4 % paraformaldehyde and
stained with Giemsa. All experiments were performed in
triplicate.
In vivo animal studies
H460-shUSP7 cells (1×106) and H460-control (1×106) cells
were subcutaneously implanted into either posterior flank of
the same nude mouse. Tumor growth was monitored every
week, and after 20 days, the tumor volumes were measured
and statistically analyzed.
Tissue microarray analysis and immunohistochemistry
TMAs were constructed as previously described [10], and
immunohistochemistry protocols were described elsewhere
[9]. USP7 antibodies (Abcam, UK) were used to detect
USP7 protein expression. The intensity of positive staining
was measured as described [10]. The intensity of USP7 pro-
tein expression was classified into high expression and low
expression according to a cutoff value of 40 %.
Statistical analysis
Statistical analyses were performed with SPSS 16.0 software
(SPSS, Chicago, IL). Cumulative survival time was calculated
by the Kaplan-Meier method and analyzed by the log-rank
test. Cox’s proportional hazards regression model was used to
analyze the independent prognostic factors. For the compari-
son of individual variables, t tests, χ2 tests, Fisher’s exact
tests, and Spearman coefficients tests were carried out as
appropriate. Statistical significance was determined for two-
tailed tests at p<0.05.
Results
USP7 is frequently upregulated in NSCLCs and positively
correlates with poor NSCLC prognosis
To investigate the USP7 expression in NSCLC tissues, we
first detected USP7 expression in 12 pairs of fresh primary
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NSCLC tumors (excluding the adenocarcinoma tissues) and
their corresponding non-tumorous tissues by qRT-PCR and
Western blot analysis. USP7 upregulation was detected in 11
out of 12 tumor tissues compared with their normal counter-
parts (Fig. 1a, b). Then, we further investigated the
USP7 protein expression in 110 primary squamous cell
carcinoma and large cell carcinoma and their adjacent
normal lung tissues by IHC using tissue microarrays
(TMA). USP7 upregulation was detected in 57 out of
110 (51.82 %) tumor tissues compared with their adja-
cent non-tumorous tissues (Fig. 1c).
Furthermore, we investigated USP7 expression in A549,
H460, H1299, H1355, 95D, and 95C NSCLC cell lines com-
pared with the immortalized lung epithelial cell line HBE by
Western blot analysis. NSCLC cells expressed high levels of
USP7 compared with immortalized lung epithelial cells
(Fig. 1d).
To investigate whether USP7 overexpression correlates
with clinical squamous cell carcinoma and large cell carcino-
ma progression, we analyzed USP7 expression in the cohort
of 110 squamous cell carcinoma and large cell carcinoma
patients. USP7 expression positively correlated with a more
advanced tumor stage (p<0.001), lymph node metastasis (p=
0.006), and bigger tumor size (p=0.038). However, there were
no significant relationships between USP7 and other factors,
such as age, gender, smoking status, and differentiation
(Table 1).
We next divided the 110 patients into two groups: those
with a high expression of USP7 (USP7high) and those with a
low expression of USP7 (USP7low). Univariate analysis re-
vealed that tumor size (≥3 cm, p<0.001), lymph node metas-
tasis (p<0.001), advanced tumor stage (p<0.001), and high
USP7 expression (p<0.001) were associated with OS
(Table 2). We subsequently analyzed the impact of USP7
Fig. 1 USP7 is frequently
upregulated in NSCLCs and
positively correlates with poor
NSCLC prognosis. a, b USP7
mRNA and protein expression in
paracancerous and cancer tissues
from squamous cell carcinoma
and large cell carcinoma patients;
c USP7 protein expression in
paracancerous and cancer tissues
from 110 NSCLC patients
determined by IHC (excluding the
adenocarcinoma); d USP7
expression in six NSCLC cell
lines and one normal bronchial
epithelial cell line; e prognostic
significance of USP7 expression
in squamous cell carcinoma and
large cell carcinoma patients
assessed by Kaplan-Meier
survival estimates
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expression on the survival of NSCLC patients. We
found that the 5-year OS in the USP7low group was
significantly higher than the USP7high group (63.7 ver-
sus 28.1 %). The multivariate Cox proportional hazards
model was used for further analysis and high USP7
expression was an independent prognostic predictor for
OS (p=0.007) (Table 2, Fig. 1e).
Large cell carcinoma cell tumorigenesis is inhibited by USP7
knockdown in vitro and in vivo
To evaluate the effect of USP7 expression on tumori-
genesis, USP7 expression was knocked down in H460
cells (a large cell lung cancer cell line) using shRNAs
(cells termed H460-shUSP7). The shUSP7 2# was the
most effective knockout sequence and used for further
experiments (Fig. 2a). Compared with control cells,
cells with an interference of USP7 effectively inhibited
cell tumorigenesis, including cell growth rate and foci
formation frequency in vitro assays (Fig. 2b, c).
To further explore the tumorigenic ability of USP7 in vivo,
tumor formation in nude mice was conducted by subcutane-
ously injecting H460-shUSP7 cells (H460-vec cells as
controls) into five nude mice. The results showed that tumor
formation in nude mice injected with H460-shUSP7 cells was
significantly suppressed (Fig. 2d, e). With qRT-PCR and
Western blot, we confirmed that USP7 was expressed higher
in H460-vec cells-derived tumors (Fig. 2f, g). These results
strongly suggest that USP7 plays vital roles in promoting
tumor development.
USP7 downregulation promotes lung cancer cell apoptosis
USP7 reportedly regulates the apoptosis process [11]. To
investigate the effect of USP7 expression on apoptosis in
NSCLC cells, annexin V-PE was used to label apoptotic cells.
We found that H460-shUSP7 cells contained a significantly
greater number of apoptotic cells than control cells (Fig. 3a–
c). Apoptosis is often triggered by p53 [12], and previous
research has confirmed that p53 is regulated by USP7 through
the oncogene MDM2 [13–15]. However, the role of USP7 in
the p53-MDM2 pathway is currently controversial [14–16].
Table 1 Clinicopathologic variables in 110 NSCLC patients
Variables No. of patient USP7 expression p value
low high
Age
<51 27 15 12 0.377
≥51 83 38 45
Gender
Male 60 28 32 0.728
Female 50 25 25
Smoker status
Smoker 31 14 17 0.691
Non-smoker 79 39 40
Tumor stage
I–II 77 46 31 <0.001
III–IV 33 7 26
Lymph node metastasis
Yes 46 15 31 0.006
No 64 38 26
Tumor size
<3 cm 49 29 20 0.038
≥3 cm 61 24 37
Differentiation
Well/moderate 74 38 36 0.340
Poor 36 15 21
Table 2 Univariate and multivariate analysis of factors associated with OS
Variables Univariate analysisa p value Multivariate analysisb p value
HR HR
Age (≥51 versus <51) 1.698 (0.882–3.267) 0.113
Gender (female versus male) 0.610 (0.362–1.028) 0.063
Smoking status (non-smoker versus smoker) 0.695 (0.403–1.198) 0.190
Differentiation
(poor versus well/moderate)
1.787 (1.064–3.002) 0.028 1.426 (0.845–2.408) 0.184
Tumor size (≥3 cm versus <3 cm) 2.854 (1.622–5.022) <0.001 2.319 (1.297–4.147) 0.005
Lymph node–metastasis (yes versus no) 3.285 (1.952–5.530) <0.001 2.467 (1.333–4.600) 0.004
Tumor stage (III–IV versus I–II) 2.864 (1.708–4.802) <0.001 1.031 (0.535–1.987) 0.927
USP7 expression
(high versus low)
2.989 (1.730–5.166) <0.001 2.244 (1.247–4.040) 0.007
OS overall survival, 95 % CI 95 % confidence interval
a Variables were adopted for their prognostic significance (p<0.05) in univariate analysis using forward, stepwise selection (forward likelihood ratio)
b A Cox proportional hazards regression model was used for multivariate analysis
Tumor Biol. (2015) 36:1721–1729 1725
Consequently, we investigated p53 and MDM2 expression
differences between H460-control and H460-shUSP7 cells.
The results showed that p53 was dramatically increased in
H460-shUSP7 compared to H460-control cells. However,
MDM2 expression was downregulated when USP7 expres-
sion was knocked down (Fig. 3d).
To elucidate the molecular basis of apoptosis inhibition
mediated by USP7, we further analyzed the effects of USP7
on the Bcl-2 protein family (mitochondrial proteins critical for
performing cell apoptosis). We found that the levels of Bcl-2,
Bcl-xL, and phosphorylated Bad were significantly downreg-
ulated after USP7 expression was knocked down (Fig. 3e). As
Bad phosphorylation is promoted through the ERK and p38-
MAPK pathways [17, 18], we examined these signaling path-
ways by Western blot analysis. However, the results showed
no significant changes in the phosphorylation levels of ERK
and p38-MAPK (Fig. 3f). The results indicated that overex-
pression of USP7 mediated apoptosis by regulating the p53-
MDM2 pathway, which resulted in the upregulation of the
Bad phosphorylation.
USP7 expression affects NSCLC cell invasiveness and cells
EMT
To investigate the impact of USP7 on cancer cell invasiveness,
we used transwell assays to study the different invasive abil-
ities between H460-shUSP7 and H460-control cells. The
knockdown of USP7 significantly inhibited cell invasiveness
(Fig. 4a, b).
Epithelial-mesenchymal transition (EMT) plays a decisive
role in cancer progression and metastasis [19]. We therefore
analyzed the relationship between the USP7 and epithelial and
mesenchymal markers expression in cancer tissues and cells.
Firstly, we found that the high level of USP7 is more often
with the low expression of E-cadherin in cancer tissues
(Fig. 4c). Consistently, we observed an upregulation in E-
cadherin protein levels, but a downregulation in Vimentin
and N-cadherin proteins levels, after USP7 knockdown by
shRNAs (Fig. 4d). These results indicated that USP7 poten-
tially participates in EMT to promote NSCLC cell
invasiveness.
Fig. 2 Large cell carcinoma cell tumorigenesis is inhibited by USP7
knockdown in vitro and in vivo. a Western blot analysis verified
vshRNA-mediated interference of USP7 expression in H460 cells; b
growth curves of H460-vshUSP7 cells compared with control cells using
the CCK-8 assay; c representative inhibition of foci formation in
monolayer culture due to the interference of USP7 expression; d, e
representative tumors formed in nude mice by control cells and H460-
vshUSP7 cells; f, g qRT-PCR and Western blot were conducted to
confirm the expression of USP7 in H460 generated xenografts
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Discussion
Considerable research has found that USP7 is critical for
controlling cell death and proliferation, and regulates key
biological signaling pathways in tumorigenesis [5, 6, 11, 19,
20]. Although, the reduction of USP7 combining with p53
gene status has been reported to be a significant indicator of
poor prognosis in adenocarcinoma patients, the roles of USP7
in lung squamous cell carcinoma and large cell carcinoma are
largely unknown. Here, our results indicate that lung squa-
mous cell carcinoma and large cell carcinoma tumors and
NSCLC cell lines express high levels of USP7 compared with
corresponding non-tumorous tissues or immortalized normal
lung cell lines. Clinically, large tumor size, advanced tumor
stage, and lymph node metastasis were associated with ele-
vated USP7 expression. Furthermore, Kaplan-Meier analysis
revealed that the patients with high USP7 levels had signifi-
cantly shorter overall survival than those with low USP7
expression in 110 squamous cell carcinoma and large cell
carcinoma patients. By knocking down USP7 expression with
shRNA interference, we revealed that lowering USP7 expres-
sion could effectively suppress cell growth rate, foci formation
in vitro, and tumor formation in vitro and in vivo. Thus, we
showed that high USP7 levels promote squamous cell carci-
noma and large cell carcinoma progression.
USP7 is known to regulate the p53-MDM2 pathway [7, 11,
13]. MDM2 is a major negative regulator of p53 [21], and
recent studies have found that p53 and MDM2 both bind to
the N-terminal TRAF-like domain of USP7 in a mutually
exclusive manner [13, 22]. Our data showed dramatic in-
creases in p53 expression and decreases in MDM2 expression
in USP7 knockdown H460 cells compared with control cells.
This suggests USP7 may negatively regulate p53 levels
through MDM2. p53 is a key protein in mitochondrial apo-
ptotic pathways [12, 23], and our research found that the
knockdown of USP7 expression in H460 cells can promote
apoptosis, again suggesting that USP7 participates in the
apoptotic pathway.
Fig. 3 USP7 downregulation promotes lung cancer cells apoptosis. a–c
Analysis of H460-vshUSP7 and control cell apoptosis using the Annexin
V-PE apoptosis detection kit; d the interference of USP7 expression
downregulated MDM2 protein expression but upregulated p53 protein
levels; e the interference of USP7 expression suppressed the anti-
apoptotic proteins Bcl-2, Bcl-xL, and phosphorylated Bad; f a compari-
son of ERK, P-ERK, and p38-MAPK protein expression between H460-
vshUSP7 and control cells by Western blot analysis
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In the mitochondrial apoptotic pathway, Bcl-2 family
apoptotic-modulating proteins are closely regulated by
p53 [12, 24]. Our data showed that the knockdown of
USP7 is associated with the downregulation of Bcl-2
and Bcl-xL anti-apoptotic proteins. As p53 can antago-
nize the anti-apoptotic effects of Bcl-2 and Bcl-xL [12],
USP7 may inhibit the Bcl-2 and Bcl-xL anti-apoptotic
effect by negatively regulating p53. Interestingly, the
level of phosphorylated Bad was also downregulated
by USP7 knockdown, and dephosphorylated Bad can
interact with Bcl-2 and Bcl-xL in mitochondria, thereby
inactivating these anti-apoptotic proteins and inducing
apoptosis [25]. Bad phosphorylation is reportedly pro-
moted through the ERK and p38-MAPK pathways [24].
Therefore, as ERK and p38-MAPK phosphorylation
levels did not significantly change after USP7 knock-
down in NSCLC cells, USP7 may directly affect the
phosphorylation status of Bad.
We found that USP7 knockdown significantly
inhibited cell invasiveness. Furthermore, upregulation
in E-cadherin protein levels, but downregulation in
Vimentin and N-cadherin proteins levels, was found
after the knockdown in USP7 levels. These results in-
dicate that USP7 may participate in EMT to promote
the invasive ability of cancer cells.
Overall, we have demonstrated that lung squamous cell
carcinoma and large cell carcinoma overexpressed USP7,
and high levels of USP7 play an important role in tumor
invasion and metastasis in squamous cell carcinoma and large
cell carcinoma. USP7 is a novel marker for predicting the
prognosis of patients with lung squamous cell carcinoma and
large cell carcinoma, and may serve as a potential therapeutic
target.
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